# OnCo record transcription-addiction (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/transcription-addiction/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "transcription-addiction" ;
  schema:name "Transcriptional machinery & addiction"@en ;
  schema:description "Cancer cells run a few genes (MYC, their lineage factors, their fusion oncogenes) at extreme volume from giant control regions called super-enhancers. The amplifiers, BRD4, CDK7, CDK9 and Mediator, are the same in every cell, but cancers are unusually dependent on them, and that dependence is druggable."@en ;
  schema:url <https://onco.cc/pathways/transcription-addiction/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Super-enhancer> ;
  schema:citation <https://doi.org/10.1016/j.cell.2016.12.013> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/ewsr1-fli1/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/targets/npm1/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/irf4/>, <https://onco.cc/targets/ikzf1/>, <https://onco.cc/targets/ikzf3/> ;
  onco:drugs <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/elacestrant/> ;
  onco:pathways <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/swi-snf-chromatin/>, <https://onco.cc/pathways/mrna-translation-eif4f/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ar-v7/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bradner-cell/> .